Bradley Canino
Stock Analyst at Guggenheim
(3.85)
# 1,966
Out of 5,162 analysts
300
Total ratings
40.3%
Success rate
5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintained: Buy | $89 → $120 | $74.74 | +60.56% | 5 | Nov 19, 2026 | |
| FTH Faeth Therapeutics | Maintained: Buy | $69 | $12.68 | +444.16% | 4 | Nov 10, 2026 | |
| CELC Celcuity | Reiterated: Buy | $175 → $169 | $70.37 | +140.16% | 17 | Nov 6, 2026 | |
| CCCC C4 Therapeutics | Reiterated: Buy | $7 → $6 | $3.15 | +90.48% | 21 | Nov 5, 2026 | |
| DMRA Damora Therapeutics | Reiterated: Buy | $60 → $59 | $24.07 | +145.12% | 7 | Nov 5, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $55 | $12.76 | +331.03% | 11 | Nov 5, 2026 | |
| KYMR Kymera Therapeutics | Rated: Buy | $135 → $170 | $138.86 | +22.43% | 22 | Aug 30, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $9.23 | +95.02% | 11 | Aug 3, 2026 | |
| SMMT Summit Therapeutics | Rated: Buy | $40 → $38 | $17.84 | +113.00% | 16 | Jul 23, 2026 | |
| ANTX AN2 Therapeutics | Initiated Coverage: Buy | $9 | $4.00 | +125.00% | 1 | Jul 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $9.55 | +224.61% | 18 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $35 | $7.36 | +375.54% | 5 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $9.98 | +320.84% | 2 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $26 | $20.39 | +27.51% | 18 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $13.65 | +156.41% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $22.30 | +142.15% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $11.73 | +155.75% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.86 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $7.57 | n/a | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $1.70 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.74 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $1.5 | $1.29 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 → $51 | $6.76 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $3.97 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $2.34 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $13.71 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $51.55 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $71.74 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $30.81 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $21.79 | n/a | 1 | Jul 8, 2020 |
CG Oncology
Nov 19, 2026
Maintained: Buy
Price Target: $89 → $120
Current: $74.74
Upside: +60.56%
Faeth Therapeutics
Nov 10, 2026
Maintained: Buy
Price Target: $69
Current: $12.68
Upside: +444.16%
Celcuity
Nov 6, 2026
Reiterated: Buy
Price Target: $175 → $169
Current: $70.37
Upside: +140.16%
C4 Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $3.15
Upside: +90.48%
Damora Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $60 → $59
Current: $24.07
Upside: +145.12%
Janux Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $55
Current: $12.76
Upside: +331.03%
Kymera Therapeutics
Aug 30, 2026
Rated: Buy
Price Target: $135 → $170
Current: $138.86
Upside: +22.43%
ORIC Pharmaceuticals
Aug 3, 2026
Reiterated: Buy
Price Target: $18
Current: $9.23
Upside: +95.02%
Summit Therapeutics
Jul 23, 2026
Rated: Buy
Price Target: $40 → $38
Current: $17.84
Upside: +113.00%
AN2 Therapeutics
Jul 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $4.00
Upside: +125.00%
Jul 14, 2026
Reiterated: Buy
Price Target: $31
Current: $9.55
Upside: +224.61%
Jun 1, 2026
Reiterated: Buy
Price Target: $38 → $35
Current: $7.36
Upside: +375.54%
May 26, 2026
Reiterated: Buy
Price Target: $42
Current: $9.98
Upside: +320.84%
May 25, 2026
Reiterated: Buy
Price Target: $22 → $26
Current: $20.39
Upside: +27.51%
Apr 29, 2026
Reiterated: Buy
Price Target: $35
Current: $13.65
Upside: +156.41%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $22.30
Upside: +142.15%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $11.73
Upside: +155.75%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.86
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $7.57
Upside: n/a
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $1.70
Upside: n/a
Mar 27, 2025
Reiterated: Buy
Price Target: $9
Current: $1.74
Upside: n/a
Mar 7, 2025
Reiterated: Hold
Price Target: $3 → $1.5
Current: $1.29
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $63 → $51
Current: $6.76
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $3.97
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $2.34
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $13.71
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $51.55
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $71.74
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $30.81
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $21.79
Upside: n/a